II. Pharmacology
- Hypersensitivity to Sulfonamide groups most affects Sulfonylarylamines, but can affect Non-Sulfonylarylamines and Sulfonamide Moieties
 - Sulfonamide Allergy does NOT cross react with sulfur, sulfate, Sulfites (e.g. Morphine Sulfate, Clopidogrel bisulfate)
 
III. Preparations: Sulfonylarylamines (Sulfa agents)
- 
                          General
- Typical sulfa-allergens, with greatest cross-reactivity to other sulfa agents
 
 - 
                          Sulfa Antibiotics
- Trimethoprim-Sulfamethoxazole (Bactrim, Sulfatrim, Co-trimoxazole, Septra)
 - Sulfadiazine
 - Sulfacetamide
 - Sulfapyridine
 
 - Sulfa Antiinflammatories
- Sulfasalazine (metabolized to sulfapyridine)
 
 - 
                          Protease Inhibitors (HIV Infection)
- Amprenavir
 - Darunavir (Prezista)
 - Fosamprenavir (Lexiva)
 - Tipranavir
 - Simeprevir (Olysio, for Hepatitis C Infection)
 
 
IV. Preparations: Non-Sulfonylarylamines
- 
                          General
- Similar structure to Sulfonylarylamines , but Hypersensitivity cross-reactivity is uncommon
 - However, do not use non-Sulfonylarylamines if history of Anaphylaxis or Erythema Multiforme Major to sulfa agents
 
 - 
                          Diuretics
- All Thiazide Diuretics
 - Some Loop Diuretics (Furosemide, Torsemide, Bumetanide)
 - Carbonic Anhydrase Inhibitors (e.g. Acetazolamide)
 
 - Anti-hyperglycemics (Diabetes Mellitus)
- Sulfonylureas (e.g. Glipizide)
 
 - 
                          Analgesics
- COX-2 Inhibitors (e.g. Celecoxib or Celebrex)
 
 
V. Preparations: Sulfonamide Moieties
- 
                          General
- Differ significantly from Sulfonylarylamines (despite both having Sulfonamide group)
 - However, do not use non-Sulfonylarylamines if history of Anaphylaxis or Erythema Multiforme Major to sulfa agents
 
 - Neurologic agents
- Triptans (e.g. Sumatriptan or Imitrex)
 - Topiramate (Topamax)
 - Zonisamide (Zonagran)
 
 - Miscellaneous agents
 
VI. References
- (2014) Presc Lett 21(2): 10-11
 - (2022) Presc Lett 29(10): 55-6
 - Ghimire (2013) J Clin Pharm Ther 38: 196–202 [PubMed]
 - Giles (2019) Pharmacy 7(3):132 +PMID: 31514363 [PubMed]
 - Wulf (2013) Am J Health Syst Pharm 70:1483-94 [PubMed]